Wall Street hails new Valeant financial chief

Investors feel Valeant Pharmaceutical's new CFO Paul Herendeen is the right prescription. Shares of the troubled Canadian drugmaker soared 8.8 percent, to $31.27, after the company announced that Herendeen replaced Robert Rosiello as chief financial officer. Rosiello will be staying on as head of corporate development and strategy. Herendeen may find familiar faces at Valeant....